首页>
外国专利>
WASTED DISEASE CONTAINING NICUTIVE OXIDE OR A UNION WHICH IS TRANSFERRED TO NICUTIVE OXIDE IN A PREPARED WASTE MATTER (DECISION), AND A CHALLENGE WHICH CONTAINS A REQUEST TO INVESTIGATE HMG-COA IN A DISPOSAL FORM
WASTED DISEASE CONTAINING NICUTIVE OXIDE OR A UNION WHICH IS TRANSFERRED TO NICUTIVE OXIDE IN A PREPARED WASTE MATTER (DECISION), AND A CHALLENGE WHICH CONTAINS A REQUEST TO INVESTIGATE HMG-COA IN A DISPOSAL FORM
This invention relates to solid oral combinations containing nicotinic acid or a nicotinic acid compound or mixtures thereof in a prolonged release (release) and a reduction inhibitor of HMC-CoA,which (pharmaceutical combinations) are useful for changing lipid levels in patients suffering fromfor example,hyperlipidaemia and arteriosclerosis,without causing drug-induced hepatic toxicity,myopathy in hyperlipidaemia,lipidaemia in undiagnosed hyperlipidaemia who have or are susceptible to cardiovascular disease and vasculitis,administering these fixed once daily combinations as a single dose during the afternoon hours,without causing drug-induced hepatic toxicity,myopathy or rhabdomyolysis,or without causing at least a significant number of people to be pharmacologically induced hepatitis,myopathy or rhabdomyolysis to such an extent as to require discontinuation of this therapy. More specifically,this invention concerns oral solid pharmaceutical combinations consisting of (1) an HMC-CoA reductase inhibitor for immediate or prolonged release,(2) nicotinic acid,a nicotinic acid compound or mixtures thereof and (3) an enlargement factor to form a compound with persistent release for:prolonged release of nicotinic acid or its compounds for evening or afternoon dosingto reduce lipid levels and increase HDL cholesterol. According to
展开▼
